Jazz Pharmaceuticals Plc - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on January 13, 2014, by Jazz Pharmaceuticals Plc, an Ireland-based pharmaceutical company. The report details a corporate overview and financial update presented at the J.P. Morgan Healthcare Conference in San Francisco on the same date.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that the company confirmed its previously issued financial guidance for the fiscal year ending December 31, 2013, which was originally provided on November 5, 2013.
Material Changes
No material changes to financial results were reported in this filing. The primary action was the confirmation of existing financial expectations for the 2013 fiscal year.
Guidance, Outlook, and Risks
Management confirmed its current expectations regarding certain financial guidance for the year ended December 31, 2013. The presentation included slides and a transcript (Exhibit 99.1) detailing this confirmation. The filing explicitly states that the information contained in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Review Exhibit 99.1 (slides and transcript) for the specific numerical details of the confirmed 2013 financial guidance.
- Compare the confirmed guidance against the original guidance issued on November 5, 2013, to ensure no subtle adjustments were made.
- Verify the company's actual performance against this guidance in subsequent quarterly or annual reports (10-Q or 10-K).
- Note the legal disclaimer that this specific presentation material is not incorporated by reference into other regulatory filings.